02496.HK
Wuhan YZY Biopharma Co Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 3.30
−8.33%Margins
Gross margin
16.3%
EBITDA margin
-105.3%
EBIT margin
-116.9%
Net margin
-114.7%
FCF margin
-48.6%
183.3%
Return on equity
-55.5%
Return on assets
-132.5%
Return on invested capital
0.48x
Asset turnover
-HKD 46.6M
Cash from operations
HKD 0.60
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Dec 1, 2025